• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » CISCRP Survey Reveals Optimism About Timing of COVID-19 Vaccine, Treatments

CISCRP Survey Reveals Optimism About Timing of COVID-19 Vaccine, Treatments

June 1, 2020

Sixty percent of the public surveyed say they believe a treatment or vaccine for COVID-19 will be developed in just under a year. And once developed, 64 percent said they thought it would be less than a year before the public could begin receiving a COVID-19 treatment or vaccine.

More North American respondents (21 percent) said it would take less than six months to develop a treatment or vaccine compared with European respondents (11 percent), according to a survey of 500 people conducted by the Center for Information and Study on Clinical Research Participation (CISCRP).

Up to 55 percent said they were willing to participant in a COVID-19 trial. More Europeans (60 percent) said they are “somewhat” or “very willing” to participate in a COVID-19 trial compared with those from North America (48 percent). Approximately 46 percent of respondents who indicated they were “somewhat” or “very willing” to participate in a COVID-19 study said they wanted to participate to advance science, help others with COVID-19 and to help researchers find a treatment for the virus. Only 17 percent and 29 percent of respondents said they wanted to participate to receive free medication or to receive money, respectively.

Of the 228 respondents who indicated they were “not sure,” “not at all” or “not very” willing to participate in a COVID-19 trial, 45 percent said they would not participate because they do not want to take a chance on their health.

The survey also found that 90 percent of 38 trial volunteers for non-COVID-19 studies are currently experiencing changes in their trial because of the pandemic. Almost half (42 percent) of these respondents said their trial has shifted to the use of telemedicine to avoid in-person site visits, and 21 percent said their study medication is now being sent to their home. Approximately 26 percent of respondents said their clinical study has been suspended altogether, whereas 11 percent indicated their number of in-person clinic visits have been reduced.

More people who previously experienced symptoms related to COVID-19 were aware of a specific COVID-19 trial (58 percent) compared with respondents who had no previous virus symptoms (34 percent). A higher proportion of respondents who had been tested for the virus were also more aware of a specific trial (62 percent) vs. those who had not been tested (34 percent).

In terms of trust, 49 percent of respondents said they held “some” trust in research centers and clinics, compared with only 29 percent of respondents who said they held “a lot” of trust in these centers. Around 50 percent said they held “some” trust in regulatory authorities, such as the FDA, and 47 percent of respondents said they held “some” trust in pharmaceutical companies. Only 17 percent of respondents reported having “a lot” of trust in pharmaceutical companies.

Approximately 89 percent of 474 respondents to the CISCRP survey said they understood clinical research “somewhat” or “very” well, and approximately 58 percent of the general public are not aware of specific clinical trials for COVID-19, while awareness of specific COVID-19 trials that were in the recruitment phase was greater among respondents who had experience participating in clinical trials (62 percent) compared with individuals who had no history of participating in a study (31 percent).

Respondents who said they were aware of a specific trial indicated they had heard about it on the TV, radio, newspaper or public transportation ads (27 percent).

To see the full results of the survey, click here: https://bit.ly/2TRIG31.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing